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Abstract
 
Two seemingly incompatible models exist to explain the progression of cancers in immuno-
competent hosts. The cancer immunosurveillance hypothesis posits that recognition of trans-
formed cells by the immune system results in the generation of an effector response that may impede
tumor growth. Clinically detectable cancer results from the emergence of tumor variants that escape
this selective pressure. Alternatively, induction of immune tolerance to tumor antigens may enable
cancer progression. We established a model where changes in the function of tumor-specific T
cells and in tumor antigen expression could be followed during cancer progression. Early recog-
nition of antigen led to activation, expansion, and effector function in tumor-specific CD4
 
 
 
 T
cells resulting in the outgrowth of tumors expressing substantially reduced levels of antigen. Antigen
loss was not complete, however, and levels remained above the threshold required for tumor-
specific T cell recognition in vivo. In the face of persisting antigen, T cell tolerance ensued,
leading to an impaired ability to mediate further antigen loss. Together, these studies establish
that the processes of immunosurveillance and tumor editing coexist with a process in which the
functional tumor-specific T cell repertoire is also “edited,” reconciling two hypotheses histori-
cally central to our attempts to understand host antitumor immunity.
Key words: immunosurveillance • immunoediting • immune tolerance • T lymphocyte • 
tumor escape
 
Introduction
 
The role played by host immunity on the development and
progression of cancer has been a subject of speculation and
experimentation for over 50 yr (1–3). In animal models, de-
ficiencies in both innate and adaptive immunity have been
associated with an increased incidence and accelerated kinetics
of tumor development induced by carcinogens, transgenic
expression of oncogenes, or even of cancers that arise spon-
taneously (4, 5). These results support the hypothesis that
the normal immune system plays a physiologic role in sur-
veying for events associated with malignant transformation
of host tissues. In immunocompetent mice, immune-medi-
ated antitumor effector responses have been demonstrated
in the early phases of tumor growth. In mice with established
tumor, such responses are even capable of rejecting a small
challenge of the same cancer type injected at a distant ana-
tomical site—so called “concomitant immunity” (6). The
identification of tumor escape variants that have lost ex-
pression of dominant antigens, have altered antigen process-
ing machinery, or have lost components required for sen-
sitivity to immune-mediated killing is compatible with
successful evasion of immunologic selective pressure, a pro-
cess termed “immunoediting” by Schreiber and colleagues
(5). Consistent with this picture of tumor progression re-
quiring adaptation and selection by host immunity, tumors
arising in immunodeficient animals (i.e., “unedited” tumors)
are frequently rejected when transplanted into syngeneic,
immunocompetent recipients but not when implanted into
secondary immunodeficient hosts (4).
Whereas expanded tumor-specific T cell populations can
often be detected in the blood or tumors of cancer patients,
consistent with host immunosurveillance, not infrequently,
cancer cells isolated from progressing tumors can still be
recognized by these T cells after their in vitro activation
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and expansion. These findings suggest that selection of less
antigenic or immunogenic tumor subclones cannot be the
sole mechanism involved in tumor evasion of host immu-
nity. In fact, even though clonal expansion of tumor-spe-
cific T cells is sometimes demonstrated in vivo, such cells
have often been shown to have impaired functional re-
sponses to antigen, especially when studied after minimal
manipulation (7). Mouse models have also demonstrated
that although early recognition of tumor antigen leads to
clonal expansion of tumor-specific T cells, such cells have
impaired responses to antigen in vitro, and their ability to
be primed in vivo is substantially diminished compared
with mice with established tumor not expressing the rele-
vant antigen, or to mice without tumor (8–10). These ob-
servations have led to the argument that tumor progression
is accompanied by the development of tumor antigen–spe-
cific T cell tolerance, perhaps through mechanisms akin to
those that regulate responses to normal self-antigens (11).
Together, these results support the hypothesis that the de-
velopment of tumor-specific T cell tolerance is a key event
in the course of tumor progression. From the perspective
of a “failed” host response to tumor, it would appear that
the ultimate outcome of an antigenic encounter by tumor-
specific T cells is the induction of specific unresponsive-
ness—a conclusion seemingly at odds with the tenor of the
immune surveillance hypothesis.
To more fully examine the immunological events that
accompany tumor progression, we established a model that
employs a defined antigen and a defined population of an-
tigen-specific T cells. By fixing these two parameters, serial
quantitative measurements of tumor antigenicity and tu-
mor-specific T cell function could be made in a single sys-
tem during tumor progression. This analysis demonstrated
that the initial recognition of an immunogenic tumor by
tumor-specific CD4
 
 
 
 T cells led to their activation, expan-
sion, and acquisition of effector function capable of select-
ing for the outgrowth of tumors with substantially reduced
levels of antigen expression. However, antigen loss was not
complete and levels presented to the immune system by
edited tumor remained above the threshold required for
recognition by tumor-specific T cells in vivo. In the face of
this persistent exposure to antigen, T cell effector function
waned, leading to T cell tolerance, and these tumor anti-
gen–experienced T cells were no longer capable of ex-
erting selective pressure sufficient for mediating tumor
antigen loss. Together, these studies establish that cancer
progression involves reciprocal changes in the antigenic
profile of the evolving tumor and in the functional capacity
of the tumor antigen–specific T cells. These changes result
in a homeostasis in which a less immunogenic tumor emerges
in the face of an immune system less capable of responding
to it.
 
Materials and Methods
 
Mice.
 
Male BALB/c (Thy1.2
 
 
 
/
 
 
 
) 6–8 wk old mice were
purchased from the National Cancer Institutes. TCR transgenic
mice on a BALB/c background expressing an 
 
  
 
 TCR specific
for amino acids 110–120 from influenza haemaglutinin (HA) pre-
sented by I-E
 
d
 
 (6.5 transgenic mice) were a gift from H. von
Boehmer (Harvard Medical School, Dana Farber Cancer Insti-
tute, Boston, MA) (12). TCR transgenic mice used in experi-
ments were heterozygous for the transgene and were also
Thy1.1
 
 
 
/1.2
 
 
 
 unless otherwise specified. Transgenic mice ex-
pressing an 
 
  
 
 TCR specific for amino acids 518–527 from HA
presented by K
 
d
 
 (CL4 mice) were a gift from L. Sherman (The
Scripps Research Institute, La Jolla, CA) (13). CL4 mice con-
genic for Thy1.1
 
 
 
/
 
 
 
 were used. BALB/c Rag 2
 
 
 
/
 
 
 
 mice were
purchased from The Jackson Laboratory. Experiments using mice
were conducted in accordance with protocols approved by the
Animal Care and Use Committee of the Johns Hopkins Univer-
sity School of Medicine.
 
Tumor Cells.
 
Renal cell carcinoma cells (Renca) were ob-
tained from the American Type Culture Collection. Cells were
cultured in vitro in RPMI 1640 media, supplemented with 10%
FCS, 50 U/ml penicillin/streptomycin, 2 mM 
 
l
 
-glutamine, and
50 mM 
 
 
 
-mercaptoethanol (complete media), and were grown at
37
 
 
 
C, 5% CO
 
2
 
. RencaHA was generated as described previously
(14). 1
 
   
 
10
 
6
 
 tumor cells in a total volume of 0.2 ml HBSS were
injected into each mouse i.v.
 
Adoptive Transfer.
 
For transfer of transgenic CD4
 
 
 
 T cells,
single cell suspensions were generated from both LNs and spleens
of TCR transgenic donors. CD4
 
 
 
 T cells were enriched by de-
pleting CD8
 
 
 
 T cells and B cells as described (15). Briefly, cells
were incubated with biotinylated antibody against CD8
 
 
 
 (53–6.7)
and CD45R/B220 (RA3-6B2). The biotin antibody–coated cells
were then removed by streptavidin-conjugated magnetic beads
(Dynal). The percentage of lymphocytes positive for CD4 and the
clonotypic TCR (mAb 6.5) was determined by flow cytometry.
Cells were washed, and 2.5
 
   
 
10
 
6
 
 CD4
 
 
 
 anti-HA TCR
 
 
 
 T cells
were injected i.v. into each recipient. Thy1.1
 
 
 
/
 
 
 
CD8
 
 
 
 T cells
from CL4 transgenic mice were purified similarly except for the
replacement of anti-CD8
 
 
 
 with anti-CD4
 
 
 
 antibody. For experi-
ments involving a cotransfer of both HA-specific CD4
 
 
 
 and
CL4CD8
 
 
 
 T cells, HA-specific CD4
 
 
 
 T cells were Thy1.2
 
 
 
/
 
 
 
.
The purity of total CD4
 
 
 
 or CD8
 
 
 
 T cells after enrichment was
usually 92 and 85%, respectively. For 5,6-carboxy-fluorescein suc-
cinimidyl ester (CFSE) (Molecular Probes) labeling, purified CD4
 
 
 
T cells were incubated with 1 
 
 
 
M CFSE at 37
 
 
 
C for 10 min and
then washed with ice cold HBSS before transfer.
To assess the tumor-editing capability of the tumor-experienced
CD4
 
 
 
 T cells, 2.5
 
   
 
10
 
6
 
 clonotypic HA-specific CD4
 
 
 
 (Thy1.1
 
 
 
)
T cells were transferred into tumor-free mice or mice with 10-d
established RencaHA. 3 wk after transfer, mice were killed and
LNs (including draining and nondraining nodes) and spleens were
recovered. Total CD4
 
 
 
 T cells were purified using CD4
 
 
 
 T cell
isolation kit (Miltenyi). These purified T cells were transferred
again into mice challenged with RencaHA 10 d earlier. Each
mouse received 2.6 
 
 
 
 10
 
6
 
 Thy1.1
 
 
 
 CD4
 
 
 
 T cells contained
within the total purified CD4
 
 
 
 T cell population. 3 wk after T cell
transfer, tumor explants were prepared, and HA levels on tumor
explants were measured by RT-PCR as described below.
 
Flow Cytometric Analysis.
 
All antibodies were purchased from
BD Biosciences unless otherwise specified. HA-specific CD4
 
 
 
TCR transgenic T cells were stained with biotinylated rat anti–
clonotypic TCR antibody 6.5 (prepared from a hybridoma) fol-
lowed by PE-conjugated streptavidin. Single cell populations
from the LNs and spleens were stained with the indicated mAbs
for cell surface markers. For analysis, 30,000 gated events were
collected on a FACSCAN (Becton Dickinson) and analyzed us-
ing CellQuest software (Becton Dickinson). 
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Bromodeoxyuridine Experiments.
 
After T cell transfer, recipient
mice were fed with bromodeoxyuridine (BrdU)-containing water
(0.8 mg/ml) at specified intervals for seven consecutive days. BrdU
water was changed daily. For analysis, cells from the hilar LNs
were isolated and stained for BrdU using the BD Biosciences
BrdU flow kit following the manufacturer instructions. For better
resolution, anti-Thy1.1 antibody was used instead of the anti-
TCR clonotypic antibody to gate on the transferred CD4
 
 
 
 T cells.
Since not all Thy1.1
 
 
 
CD4
 
 
 
 cells were transgenic cells, in parallel
to BrdU staining, each sample was stained with anti–Thy1.1-
FITC, anti–CD4-Cyc, and anti-TCR clonotypic antibodies fol-
lowed by streptavidin-PE to obtain the percentage of HA-specific
cells in the Thy1.1
 
 
 
CD4
 
 
 
 population. BrdU staining on cells from
tumor-free mice was taken as background and was subtracted from
the percentage of the BrdU
 
 
 
 cells in the Thy1.1
 
 
 
CD4
 
 
 
 popula-
tion in tumor-bearing mice. The net value was then normalized to
the percentage of HA-specific CD4
 
 
 
 cells to get the percentage of
BrdU
 
 
 
 cells in the HA-specific CD4
 
 
 
 population.
 
Immunohistochemistry.
 
Lung tissues were harvested from mice.
Tissue was fixed for 3 d at 4
 
 
 
C and then embedded in Immuno-
HistoWax (A Phase sprl). Serial sections were stained using biotin-
labeled anti-HA mAb (H18). The Vectastain ABC kit (Vector
Laboratories) and NovaRed (Vector Laboratories) were used for
development. Sections were counterstained with hematoxylin QS
(Vector Laboratories) and analyzed using a Nikon Eclipse E400.
Final image processing was performed using Adobe Photoshop.
 
Real-Time RT-PCR Analysis of Explants.
 
Mice were killed
31 d after tumor injection. Lungs were dissected and rinsed with
HBSS. Single cell suspensions were made by mechanical dissocia-
tion and passage through nylon mesh. Nonadherent cells were
removed after overnight culture, and adherent tumor cells were
grown without drug selection for 1–2 wk to allow the tumor
cells to expand and any contaminating, nonadherent cells to be
removed. Cultures were washed twice with HBSS, and adherent
cells were then collected after trypsinization. For experiments in
which explanted tumors were passaged into secondary recipients,
the growth kinetics were noted to be slightly faster than that of
cultured RencaHA
 
hi
 
 cells, reflecting the selection and/or adapta-
tion of the explants for in vivo growth. However, all groups had
significant tumor burdens by 17 d after tumor challenge when T
cell recognition was assessed.
For experiments where HA message was measured, RNA was
extracted from 1 
 
  
 
10
 
6
 
 cells with Trizol (Invitrogen). Reverse
transcription was performed with the SuperScript First-Strand
Synthesis System (Invitrogen). cDNA amounts were analyzed by
real-time quantitative PCR with the Taqman System (Applied
Biosystems). Each sample was assayed in triplicate for HA to-
gether with the internal reference, HPRT, using the Taqman
Universal PCR Master Mix and the ABI Prism 7700 Sequence
Detection System (Applied Biosystems). The relative HA mRNA
frequencies were determined by normalization to HPRT. Fold
differences between samples were calculated as follows: one cycle
difference between samples is equivalent to a twofold difference
in transcript. cDNA from RencaWT cells was included in each
set of experiments as a negative control. The primer sequences
for HA were 5
 
 
 
-CGCCGGATGGCTCTTG-3
 
 
 
 (forward) and
5
 
 
 
-ACAATGTAGGACCATGATCTCACTG-3
 
 
 
 (reverse). The
HA-specific probe sequence was 5
 
 
 
-6FAM-AAACCCAGAAT-
GCGACCCACTGCTTTAMRA-3
 
 
 
In Vivo Priming with Vaccinia-HA.
 
A recombinant vaccinia
virus encoding HA from the 1934 PR8 strain of influenza
(vacHA) was a gift from F. Guarnieri (Johns Hopkins University,
Baltimore, MD). VacHA was amplified as described previously
(9). On the days indicated, mice were primed by i.p. inoculation
with 1 
 
  
 
10
 
7
 
 plaque-forming units of recombinant vacHA sus-
pended in HBSS.
 
IFN-
 
 
 
 ELISPOT.
 
5 
 
  
 
10
 
5
 
 cells from hilar LNs were plated
into wells with or without the addition of 10 
 
 
 
g/ml of synthetic
Figure 1. Recognition of antigen by tu-
mor-specific CD4  T cells. CFSE-labeled
HA-specific CD4  T cells were transferred
into mice inoculated with RencaHA 10 d
earlier. On days 7 and 21 after T cell trans-
fer, expansion of the transgenic CD4  T
cells was revealed by staining with anti-
TCR clonotypic antibody and anti-Thy1.1.
(A) FACS profiles of the transgenic CD4 
T cells in hilar draining LNs. CFSE histo-
grams of the gated cells are also shown. Per-
centage of the gated population is displayed
in each dot plot. For CFSE profiles, per-
centage of the divided cells in the gated
population is indicated in each histogram.
For comparison, CFSE-labeled HA-specific
CD4  T cells were transferred into tumor-
free mice. Some were given vacHA the
next day and analyzed 6 d later. (B) Per-
centage of the transgenic CD4  T cells in
spleen. Spleen cells from the same mice as in
A were stained and analyzed by flow cytome-
try. The results are representative of three
experiments with three mice per group. 
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HA
 
110–120
 
 peptide (SFERFEIFPKE), incubated at 37
 
 
 
C over-
night, and assayed as described previously (15).
 
Results
 
Tumor-specific CD4
 
 
 
 T Cells Acquire Effector Function dur-
ing Initial Encounter with Antigen.
 
RencaHA is a stable
transfectant of a renal cell carcinoma that expresses influ-
enza HA as a model tumor antigen. i.v. injection of
RencaHA results in the formation of multiple pulmonary
tumor nodules that are lethal after 
 
 
 
5 wk. Previous studies
demonstrated that although this tumor fails to metastasize
from the lungs to regional lymphatics, HA antigen is recog-
nized by HA-specific T cells in the hilar LNs in a process
that requires antigen processing and presentation by BM-
derived APCs (16). To determine the impact of antigen
recognition on the function of tumor-specific T cells,
CD4
 
 
 
 T cells were purified from TCR transgenic mice
specific for an MHC class II epitope of HA, labeled with
CFSE, and transferred either into mice that had been chal-
lenged with RencaHA 10 d earlier or into nontumor bear-
ing mice (Fig. 1). 7 d after T cell transfer, clear evidence of
antigen recognition was observed in the hilar LNs of tu-
mor-bearing mice, as indicated by the increased frequency
(1.27 vs. 0.02%) and CFSE dilution (79.5 vs. 3%) of HA-
specific T cells compared with nontumor bearing mice.
Given the regional distribution of the tumor, these changes
were much more modest in the spleens. 2 wk later (31 d af-
ter tumor challenge), gross examination of the lungs re-
vealed extensive studding with macroscopic tumor nodules
bilaterally. The frequency of HA-specific CD4
 
 
 
 T cells in
the hilar nodes was still expanded relative to that observed
in nontumor bearing mice, although some degree of con-
traction had occurred during this interval in mice with pro-
gressing RencaHA (1.27% on day 7 vs. 0.87% on day 21).
For comparison, nontumor bearing mice that had received
the same number of CFSE-labeled HA-specific CD4
 
 
 
 T
cells were challenged i.p. with a recombinant vaccinia virus
encoding HA (vacHA) and analyzed 6 d later. The magni-
tude of HA-specific CD4
 
 
 
 T cell expansion in the hilar
nodes was comparable to that seen in mice with RencaHA
lung metastases (1.32 vs. 1.27%, respectively), although the
accumulation of HA-specific T cells that underwent exten-
sive division was greater in response to virus than in re-
Figure 2. Early recognition of HA results
in effector function of tumor-specific T
cells. (A) T cell transfer was conducted as
described in Fig. 1. IFN-  ELISPOT was
performed with cells from hilar LNs in each
well   HA peptide. The number of IFN- –
positive spots was obtained by subtracting
the number of spots in the no peptide group
from the number of spots in the peptide
group. The results are mean   SD of
pooled data from two separate experiments.
(B) Activated CD4  T cells provide help for
CTL priming. Purified CD8  T cells from
CL4 transgenic mice on Thy1.1 back-
ground were transferred either alone or to-
gether with HA-specific CD4  T cells
(Thy1.2 ) to tumor-free or tumor-bearing
mice (10 d tumor). 7 d after T cell transfer,
cells from draining LNs were stained for the
transferred CD8  T cells with antibody to
Thy1.1 and CD8. For CD4  T cells, cells
were stained with anti-TCR clonotypic anti-
body and anti-CD4. Percentage of the gated
population is given in each dot plot. The
results are representative of two experiments
with three mice per group. 
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sponse to tumor. Not surprisingly, in the context of sys-
temic infection with vacHA the total HA-specific T cell
expansion was also greater than in response to localized tu-
mor, as indicated by their increased frequency in the
spleens (and other LNs [unpublished data]) of virally in-
fected mice.
During the early phases of antigen recognition, the ex-
panded HA-specific T cells in the hilar nodes of RencaHA-
bearing mice differentiated into cells capable of making in-
terferon gamma (IFN-
 
 
 
) (Fig. 2 A), albeit to a lesser extent
than T cells from vacHA-primed, nontumor bearing mice.
Interestingly, 2 wk after this initial endogenous activation
of tumor-specific T cells the frequency of HA-specific
IFN-
 
 
 
–producing T cells fell toward baseline in association
with tumor progression.
Early Recognition of Antigen by Tumor-specific CD4  T
Cells Augments the Expansion of Tumor-specific CD8  T
Cells. Theses changes observed during the initial phases
of antigen recognition by tumor-specific CD4  T cells
(entry into the cell cycle, clonal expansion, and the pro-
duction of IFN- ) are all features associated with CD4  T
cell effector function. To further evaluate if these changes
truly reflect a developing effector response, we examined
another important parameter of CD4  T cell function, i.e.,
the ability to provide help for the activation of MHC class
I–restricted CD8  T cells (Fig. 2 B). As seen above with
CD4  T cells, the transfer of MHC class I–restricted, HA-
specific CD8  T cells from TCR transgenic mice (CL4
mice) into mice with established RencaHA resulted in
their expansion during the first week after transfer (no tu-
mor 0.03% vs. RencaHA 0.16%). However, the magnitude
of the CD8  T cell “burst” in response to recognition of
tumor antigen was increased threefold (0.16–0.48%) when
these cells were cotransferred with HA-specific CD4  T
cells. Together, therefore, the initial recognition of tumor
antigen by tumor-specific CD4  T cells is accompanied by
their clonal expansion (0.13–1.6% in this experiment), Th1
cell differentiation, and the delivery of help for the activa-
tion of tumor-specific CD8  T cells, all consistent with an
effector response.
Early Activation of Tumor-specific CD4  T Cells Alters the
Antigenic Profile of Progressing Tumor. We therefore wished
to examine whether this initial effector response led to
measurable antitumor immunity. Previous studies demon-
Figure 3. Immunoediting of
RencaHA by the endogenous
repertoire and by transferred,
HA-specific CD4  T cells. Mice
were injected with 106 tumor
cells i.v. Mice in group D received
HA-specific CD4  T cells 10 d
posttumor. All mice were killed
at 25 d posttumor inoculation.
Lung tissue was harvested, and
sections were stained with anti-
HA antibody and developed
with NovaRed (red staining).
Sections were counterstained
with hematoxylin. (A, C, and D)
BALB/c mice; (B) BALB/c Rag
2 /  mice.Cancer Immunosurveillance and Tumor-specific T Cell Tolerance 1586
strated that the transfer of HA-specific CD4  transgenic T
cells into mice 10 d after an i.v. challenge with RencaHA
led to a slight prolongation of survival (7–10 d) over mice
not receiving T cell transfer (16). The effect of T cell trans-
fer on the level of HA expression by the progressing tumor
was examined by immunohistochemistry (Fig. 3). Whereas
HA was uniformly expressed by the cells comprising the
tumor nodules arising in RAG knockout mice challenged
with RencaHA, the level of HA expression was consider-
ably reduced and was more heterogeneous in the tumors
found in immunocompetent BALB/c recipients, demon-
strating that the endogenous adaptive immune response
was capable of some degree of immunoediting of this anti-
genic tumor. The transfer of HA-specific CD4  T cells
into BALB/c mice with established RencaHA further re-
duced the number and size of the tumor nodules compared
with no T cell transfer. Strikingly, HA expression was un-
detectable in such nodules as measured by this technique.
Indeed, the level of HA expression on tumor explants from
mice that received transgenic T cells was indistinguishable
from background staining by flow cytometric analysis as
well (unpublished data). Therefore, the initial activation re-
sulted in the selection of tumor escape variants that lost ex-
pression of the target antigen.
From the perspective of assessing the outcome of antigen
recognition by HA-specific CD4  T cells, complete eradi-
cation of cells expressing the target antigen could be
viewed as a successful effector response, in spite of the ulti-
mate progression of tumor. Therefore, it was important to
determine if the tumors that progressed in mice receiving
transgenic T cells had any residual HA expression as de-
tected by more sensitive techniques. RencaHA was excised
from the lungs of BALB/c mice that either had or had not
previously received HA-specific CD4  T cells. RNA was
isolated from the tumor cells, and the relative amount of
messenger RNA encoding HA was determined by quanti-
tative real-time RT-PCR (qRT-PCR) (Fig. 4). Compared
with cultured RencaHA cells, tumor cells obtained from
the lungs of immunocompetent mice had about an eight-
fold reduction in HA message. Importantly, tumors isolated
from mice that had received HA-specific CD4  T cells still
had detectable HA mRNA, in spite of the loss of detectable
HA protein as measured by antibody staining. T cell trans-
fer resulted in at least a 180-fold reduction of HA message
below what was achieved with the endogenous BALB/c T
cell repertoire alone (range 180–1,448 fold).
Edited Tumor Is Still Detectable by Tumor Antigen–specific T
Cells. Although PCR was able to detect HA message
from tumor that had been edited by HA-specific CD4  T
cells, the most relevant parameter pertaining to the func-
tion of the responding T cells is whether edited tumor ex-
presses protein antigen at levels sufficient for continued
recognition by the antigen-specific T cells. To determine
this, we evaluated the T cell recognition of RencaHA cells
that had never been passaged in vivo (RencaHAhi) versus
explanted tumor cells that had been edited by the endoge-
nous BALB/c immune system (RencaHAendog), versus ex-
planted tumor cells edited in BALB/c mice adoptively
transferred with HA-specific CD4  transgenic T cells
(RencaHATCR-Tg) (Fig. 5). In the absence of antigen, trans-
genic T cells fail to divide, as seen in mice with Renca
wild-type tumor. Not surprisingly, extensive division of
HA-specific T cells is seen in mice with both RencaHAhi
and RencaHAendog. However, although the transfer of HA-
specific CD4  T cells results in substantial reduction in the
level of HA expressed by the antigen loss variants (Figs. 3
and 4), the results of this experiment clearly demonstrate
that the amount of HA produced by edited tumor (Renca-
HATCR-Tg) is still sufficient to be detected by T cells having
the identical specificity and affinity for antigen as the cells
responsible for the initial editing.
Kinetics of Tumor-specific T Cell Proliferation during Tumor
Progression. Given the changes in HA expression by
RencaHA during tumor progression, we wished to exam-
Figure 4. HA mRNA frequencies on tu-
mor explants as revealed by qRT-PCR.
Tumor explants from mice with and with-
out HA-specific T cell transfer were generated
as described. Each explant or RencaHA cell
line was assayed in triplicate using probe/
primer set specific for HA. Samples were si-
multaneously assayed for HPRT which was
used as an internal reference. The cDNA
concentration of each sample was adjusted
so that HPRT amplification was equivalent
in all samples. Data shown are representative
of two separate reactions with similar results.Zhou et al. 1587
ine the kinetics of HA-specific T cell recognition in vivo
beyond the initial events captured by CSFE dilution profil-
ing. Mice with or without established RencaHA were in-
jected with HA-specific CD4  T cells and then placed on
drinking water containing BrdU during the intervals out-
lined in Fig. 6. Consistent with the earlier results using
CFSE, T cell recognition of HA during the first week led
to significant incorporation of BrdU by dividing HA-spe-
cific CD4  T cells (69.7%). Interestingly, a sizable fraction
of this tumor-specific T cell population that responded to
Figure 5. Edited tumor cells are recog-
nized by naïve HA-specific CD4  T cells.
Mice were challenged with RencaHA. 10 d
later, half of the mice received HA-specific
CD4  T cells. 21 d after T cell transfer, the
tumors were harvested from the lungs and
briefly expanded in vitro in the absence of
drug selection. A second cohort of mice was
then injected with either Renca WT cells,
RencaHA cells that had never been passaged
in vivo (RencaHAhi), RencaHA cells ex-
planted from BALB/c mice that did not
receive T cell transfer (RencaHAendog), or
RencaHA cells explanted from mice that
had received HA-specific CD4  T cells
(RencaHATCR-Tg). 10 d after tumor chal-
lenge, all mice were injected with naïve
CFSE-labeled HA-specific CD4  T cells. 7 d
later cells were isolated from hilar LNs.
Lymphocytes were stained with anti-Thy1.1
antibody and anti-TCR clonotypic anti-
body and analyzed by flow cytometry. Results
are gated on Thy1.1  cells.
Figure 6. The kinetics of tu-
mor-specific CD4  T cell prolifer-
ation during tumor progression.
Mice that received HA-specific
CD4  (Thy1.1 / ) T cells were
provided with BrdU-containing
water at the specified interval.
On the day of analysis, cells from
the hilar LNs were isolated and
stained for surface markers CD4
and Thy1.1, followed by inter-
cellular BrdU staining. The data
are representative of two separate
experiments with similar results.Cancer Immunosurveillance and Tumor-specific T Cell Tolerance 1588
antigen during the first week persisted throughout the
course of tumor progression, as indicated by the continued
detection of BrdU-positive cells in the hilar LNs 2 wk after
removing BrdU from the drinking water (32.5%). In con-
trast to the robust proliferative response observed during
the initial encounter with antigen, there was a sharp decline
in the proliferation of HA-specific CD4  T cells during the
third week after T cell transfer, as measured by BrdU label-
ing during this interval (12.4%).
Loss of the Capacity for Tumor Editing by Antigen Experi-
enced, Tumor-specific T Cells. On one level, these results
indicate that the kinetics of T cell proliferation during tu-
mor progression reflect the changing antigen density of the
tumor cells to which they are responding. However, this in-
terpretation likely oversimplifies the complexity of assessing
regional antigen density of a logarithmically expanding tu-
mor burden and the parameters that govern how much an-
tigen is captured and concentrated by APCs. In fact, in ex-
periments where the HA-specific T cell transfer was delayed
until 3 wk after RencaHA was established (a time when the
endogenous host response has selected for growth of lower
HA expressing tumor), extensive expansion and CFSE dilu-
tion of HA-specific T cells was observed (unpublished data).
Therefore, an alternative interpretation of the declining
proliferation rate of HA-specific T cells measured during
the latter stages of tumor progression is that there is an in-
trinsic change in the functional responsiveness of the tumor-
specific CD4  T cells over time. Consistent with this hy-
pothesis, previous results in this system demonstrated that
HA-specific CD4  T cells in mice with established RencaHA
tumor have a markedly impaired response to vacHA immu-
nization compared with what is observed in vaccinated,
nontumor bearing mice (16).
In reconciling these intrinsic changes in tumor-specific T
cell function with the demonstrated capacity of such cells to
edit tumor antigenicity, we wished to examine whether an-
tigen-experienced T cells from tumor-bearing mice were
altered in their capacity to exert immunologic selective
pressure on progressing tumor (Fig. 7). HA-specific CD4 
T cells were transferred into mice with or without estab-
lished RencaHA. 3 wk after T cell transfer, total CD4  T
cells were purified from the spleens and LNs and then trans-
ferred into secondary RencaHA-bearing recipients. 3 wk
later, tumor was harvested from the lungs and the relative
level of HA mRNA was determined by qRT-PCR. As
seen previously, the endogenous host response of BALB/c
mice resulted in an approximate 8–16-fold reduction in HA
message of explanted RencaHA compared with cultured
RencaHA. Transfer of CD4  T cells from nontumor bear-
ing mice that had previously received HA-specific CD4  T
cells resulted in a  500-fold further reduction of HA mes-
sage by the selected tumor (Fig. 7, dark green curve versus
dark blue). In contrast, CD4  T cells from RencaHA-bear-
ing mice were significantly less effective in editing RencaHA
in the secondary recipients (16–64-fold reduction in HA
message compared with no T cell transfer; Fig. 7, dark
green curve versus light green). This result demonstrates
that changes in tumor-specific T cell function occur over
Figure 7. Antigen-experienced, tumor-
specific T cells have a decreased ability to
edit tumor. HA-specific CD4  T cells were
transferred into tumor-free or tumor-bearing
mice. 21 d later, spleens and LNs were har-
vested from the mice. CD4  T cells were
enriched and retransferred into mice with
established RencaHA tumor. 3 wk after T
cell transfer, tumor explants were harvested
and processed. Shown are real-time RT-
PCR results for HA mRNA frequencies on
tumor explants. Each sample was assayed in
triplicate, with HPRT included as internal
reference. Each group consisted of two to
three mice.Zhou et al. 1589
time in the face of persisting antigen, impairing the capacity
of host immunity to exert selective pressure on tumor
growth. Ultimately, equilibrium is achieved in which the
antigenic profile of the resulting tumor and the functional
capacity of the tumor antigen–specific T cell repertoire are
reciprocally shaped allowing for tumor progression.
Discussion
The cancer immunosurveillance hypothesis, which had
been largely discarded for many years, has recently under-
gone an extensive reexamination with the current tools of
molecular immunology (17). Studies in mice with selective
defects in innate and/or adaptive immunity have yielded
strong evidence that host immunity plays a significant role
in altering the incidence and kinetics of cancer develop-
ment and in shaping the immunogenicity of tumors that
arise. In humans, histopathologic and molecular profiling of
tumor specimens have revealed significant correlations be-
tween the presence of immune cell infiltrates and disease
outcome, supporting the view that the host response can
have a meaningful impact on the clinical behavior of malig-
nancy (18). Similarly, the pathology literature provides am-
ple documentation of metastases frequently displaying
altered expression of immunologically relevant targets com-
pared with early stage primary cancers as evidence for tu-
mor adaptation to immunologic selective pressure (19).
The reciprocal question of how tumor progression influ-
ences the function of tumor antigen–specific T cells has
also been examined in several experimental model systems
and in patients with cancer. These studies have demon-
strated diverse outcomes ranging from T cell ignorance (20,
21) to induction of effector function (22, 23) to the dele-
tion or development of anergy of tumor-specific T cells (8,
9, 24–26). Several parameters are likely to influence which
of these outcomes predominate. Anatomic localization of
tumor has been shown to alter not only the likelihood of
tumor antigen recognition but also the pathways of presen-
tation (directly by tumor cells versus indirectly by APCs) to
tumor-specific T cells (27, 28). For nonhematopoietic can-
cers, disruption of normal tissue architecture, hypoxia-
induced cell death, tumor transit across basement mem-
branes, and systemic dissemination increase the probability
of detection. These very processes are also thought to pro-
vide signals to innate immunity which detects a “stress sig-
nature” by cancer cells and supporting stroma. In fact, one
of the earliest adaptations by tumor to this response may be
the elaboration of signals to suppress the stress signature or
the response to it (29), such as those mediated by STAT-3
(30, 31), TGF-  (32), and vascular endothelial growth fac-
tor (33) in a pattern analogous to what is seen with wound
healing. Consistent with this notion, cancer cells that dis-
play blunted stress responses, such as reduced induction of
heat shock proteins, have been shown to be relatively less
immunogenic (34, 35).
Ultimately, eliciting T cell immunity in settings such as
those studied here requires tumor antigen capture and pro-
cessing by BM-derived APCs (16, 36). Again, the likeli-
hood of T cell recognition and the outcome of that recog-
nition are influenced by several parameters, including
features intrinsic to the antigen such as the presence of can-
didate T cell epitopes capable of being liberated by the
cells’ antigen processing machinery and fitting the host’s
MHC binding motifs (37), tumor antigen density (38), the
rate of antigen liberation by dying tumor cells, the presence
of inflammatory signals to influence the function of anti-
gen-loaded APCs (39), and the frequency (40) and avidity
of functionally competent tumor-specific T cells.
In this paper, we examined both sides of this process in a
single model system in which two of the key variables listed
above were defined (i.e., tumor antigen– and antigen-spe-
cific T cells), enabling a quantitative assessment of changes
in each during tumor progression. Operationally, RencaHA
is an immunogenic tumor. We have reported previously
that it is spontaneously rejected when given as a s.c. tumor
challenge in BALB/c mice but not in mice tolerant of HA
by virtue of its transgenic expression as a self-antigen (14).
The level of HA expression on RencaHA tumor cells is
heterogeneous (in spite of limiting dilution cloning), and
i.v. injection into immunocompetent mice results in the
outgrowth of lung nodules that express less HA than the
parental clone or than the nodules that develop in RAG / 
mice (Figs. 3 and 4). This result provides a quantitative
demonstration of the endogenous response altering the an-
tigenic profile of tumor escape variants (Fig. 4), as has been
reported qualitatively in other systems. By transferring a
fixed number of HA-specific CD4  transgenic T cells hav-
ing a given affinity for HA peptide–MHC class II complexes,
we were able to follow the fate of this tumor-specific
CD4  T cell population through distinct phases of the re-
sponse to tumor antigen and superimpose these events on
the changing antigenic profile of the tumor.
The early events after HA-specific CD4  T cell transfer
clearly demonstrate tumor antigen recognition in the re-
gional (hilar) LNs draining the lungs, which is the major site
of tumor growth. Previous studies in this model established
that RencaHA in the lungs fails to metastasize to the hilar
LNs (as measured by HA-specific PCR) and that host APCs
are required for CD4  T cell recognition to occur (16).
Therefore, this initial recognition suggests that some degree
of tumor antigen liberation and capture by APCs occurs in
the early stages of tumor growth. During this phase, tumor-
specific CD4  T cell recognition results in cell division
(CFSE dilution), clonal expansion in the regional LNs, dif-
ferentiation into cells capable of producing IFN- , and the
provision of help for CD8  T cell activation (Figs. 1 and 2).
Whereas these events are typically associated with a devel-
oping effector response, some of these features are also ob-
served during the development of CD4  T cell anergy in
response to tumor (9), self antigen (41), or even to experi-
mental injection with peptide antigen (42, 43). Ultimately,
the gold standard for ascribing the functional significance of
the observed changes in tumor-specific CD4  T cells is
their impact on tumor growth. RencaHA-bearing mice that
received HA-specific CD4  T cells had diminished tumor
burdens compared with those without T cell transfer (asCancer Immunosurveillance and Tumor-specific T Cell Tolerance 1590
measured by lung weight and the number of tumor nodules
[unpublished data]). More significantly, the expression of
the target antigen by progressing tumor was dramatically re-
duced in recipients of HA-specific CD4  T cells (Figs. 3
and 4; a two to three log reduction in HA message below
the levels expressed by tumors arising in immunocompetent
mice without T cell transfer).
The mechanism(s) responsible for the CD4  T cell–
dependent effector response seen in this model are not yet
fully defined. RencaHA is constitutively MHC class II neg-
ative, but its expression is induced by IFN- , so direct rec-
ognition by CD4  T cells in the effector phase has not
been formally ruled out. Studies in parent → F1 chimeras
have shown a critical role for APCs in the initiation phase
of T cell recognition (16). During this phase, early activa-
tion of HA-specific CD4  T cells can provide help for
CD8  T cell priming (Fig. 2 B). Although CD8  T cell–
dependent mechanisms may contribute to tumor rejection,
the transfer of purified HA-specific CD4  T cells into
RAG /  mice with established RencaHA lung masses re-
sults in the near complete eradication of the tumor (unpub-
lished data), demonstrating that CD8  T cell independent
mechanisms may also be operative as has been previously
reported in related systems (44–46).
In spite of the significant antitumor effector response ini-
tially generated against this immunogenic tumor, tumors that
escape this response continue to express low levels of the
model antigen (Fig. 4). More importantly, the amount of an-
tigen produced by edited tumor was sufficient to be recog-
nized in vivo by CD4  HA-specific T cells expressing the
same clonotypic TCR as the cells responsible for the initial
editing (Fig. 5). Therefore, in spite of the changing antigen
load it is likely that antigen-experienced tumor-specific T
cells continue to be presented antigen throughout the course
of tumor progression, never achieving sterile immunity.
In several in vivo systems, the persistence of antigen has
been shown to correlate with the induction of antigen-spe-
cific T cell tolerance—either through anergy or deletion
(47, 48). In the current model, several lines of evidence
suggested that in the face of continued exposure to tumor
antigen, the initial effector response elicited by CD4  HA-
specific T cells decayed. First, although the early expansion
of this population was accompanied by a fraction of these
cells acquiring the capacity to produce IFN- , the detec-
tion of IFN-producing cells was transient (Fig. 2 A), even
though a sizable population of expanded HA-specific
CD4  T cells remained (Fig. 1). Second, the proliferation
of tumor-specific CD4  T cells fell dramatically between
the first and third weeks after T cell transfer (Fig. 6).
Whereas this may be partly due to falling antigen load, this
parameter is difficult to quantify given the opposing influ-
ences of decreasing expression of HA on a per cell basis but
increasing overall tumor burden with time. Third, previous
studies in this system have demonstrated that tumor anti-
gen–experienced HA-specific T cells had diminished re-
sponses to systemic challenge with vacHA(16), as opposed
to what might be expected for true memory cells that sur-
vive the contraction phase of an effector response. Finally,
CD4  T cells from RencaHA bearing mice were signifi-
cantly less potent than those from nontumor bearing mice
at exerting selective pressure for HA loss by progressing tu-
mor in secondary recipients (Fig. 7). Together, recognition
of tumor antigen led to expansion and contraction of an
acute response but without the development of memory.
This decay in endogenous effector function and diminished
responsiveness to exogenous priming correlated with a loss
of editing capacity.
There are now several studies examining the pathways
by which a population of effector and/or memory T cells
may become tolerant (41, 49–51). In considering the
mechanisms underlying this transition, it is important to
emphasize that the operational definition of tolerance in
such settings applies to the functional capacity of a popula-
tion of T cells of a given specificity. Much like the difficult
problem of tracking the precursor–product relationship be-
tween effector cells and memory T cells (52), it is unclear
whether tumor-specific effector cells in this model are di-
rectly rendered unresponsive, or are deleted, leaving be-
hind a population of anergized cells that never fully dif-
ferentiated into effector cells when initially activated.
Alternatively, a third possibility is that some fraction of the
effector cells do survive the contraction to become mem-
ory cells (as in antiviral responses) but that their function is
masked by an emerging population of tumor-specific sup-
pressor cells. One of the unexpected findings in the BrdU
experiment (Fig. 6) was that tumor-specific T cells that had
responded to antigen in the first week after transfer per-
sisted at a relatively high frequency (32.5%) in the hilar
nodes for the duration of the experiment. In a related
(though less immunogenic) tumor model, we now have
evidence that such long-lived tumor antigen–experienced
CD4  T cells are potent suppressors of both naïve and Th1
effector cells specific for tumor antigen (unpublished data).
Accordingly, the population of CD4  T cells specific for a
given tumor antigen may be functionally heterogeneous,
containing a mixture of naïve, effector–memory, and sup-
pressor T cell subpopulations. In such a model, the overall
functional responsiveness may reflect the relative abun-
dance of each.
Over 20 yr ago, Robert North and colleagues performed
an extensive analysis of the host response to immunogenic
tumors and demonstrated the early induction of an effector
T cell response capable of rejecting a contra lateral tumor
challenge in mice in which the initial tumor grows pro-
gressively (53, 54). Further evidence for this concomitant
immunity was demonstrated by the passive transfer of Ly-
1-2  (i.e., CD8 ) T cells isolated from mice with early
stage tumor into irradiated tumor-bearing recipients, which
led to tumor rejection. However the capacity to transfer
immunity decayed when taken from donors bearing later
stage tumor, and this decay was shown to be mediated by
the progressive accumulation of a population of Ly-1 2 
(i.e., CD4 ) suppressor T cells. Like the immunosurveil-
lance hypothesis before it, the significance of concomitant
immunity and tumor-specific suppressor T cells was largely
disputed in the absence of more defined mechanisms re-Zhou et al. 1591
sponsible for these observations. In the face of renewed in-
terest in active T cell regulation and with the availability of
new tools with which to approach the problem, the identi-
fication of such mechanisms may soon be forthcoming.
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